Published in PLoS One on July 28, 2017
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res (2011) 13.63
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Type 2 diabetes as an inflammatory disease. Nat Rev Immunol (2011) 8.30
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 7.55
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation (2003) 6.99
Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. Clin Trials (2008) 3.24
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care (2002) 3.00
Dietary pattern, inflammation, and incidence of type 2 diabetes in women. Am J Clin Nutr (2005) 2.82
Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care (2008) 2.57
Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ (2015) 2.42
The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol (2008) 2.13
Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care (2003) 2.05
Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res (2001) 1.89
C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia (2004) 1.85
Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care (2007) 1.80
Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care (2013) 1.77
Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism (2002) 1.68
Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study. Cancer Epidemiol Biomarkers Prev (2011) 1.60
Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst (2013) 1.59
Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res (2012) 1.55
Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia (2002) 1.49
C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol (2003) 1.43
Ascertainment of chronic diseases using population health data: a comparison of health administrative data and patient self-report. BMC Public Health (2013) 1.42
Diverse effect of inflammatory markers on insulin resistance and insulin-resistance syndrome in the elderly. J Am Geriatr Soc (2004) 1.36
Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst (2014) 1.34
Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am J Epidemiol (2002) 1.32
Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study. Diabetologia (2009) 1.30
Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia (2006) 1.28
IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes (2006) 1.18
Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care (2008) 1.14
A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. Blood (2013) 1.14
Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes Metab (2013) 1.09
The lack of utility of circulating biomarkers of inflammation and endothelial dysfunction for type 2 diabetes risk prediction among postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med (2010) 1.08
Inflammation and type 2 diabetes: results from KORA Augsburg. Gesundheitswesen (2005) 1.04
Improvement in β-cell function after diet-induced weight loss is associated with decrease in pancreatic polypeptide in subjects with type 2 diabetes. J Diabetes Complications (2012) 1.04
Validity of diabetes self-reports in the Women's Health Initiative. Menopause (2014) 1.03
Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Gynecol Oncol (2014) 1.01
Body mass index, physical activity, and serum markers of inflammation, immunity, and insulin resistance. Cancer Epidemiol Biomarkers Prev (2014) 1.01
The entero-insular axis in type 2 diabetes--incretins as therapeutic agents. Exp Clin Endocrinol Diabetes (2001) 0.98
Macrophages and islet inflammation in type 2 diabetes. Diabetes Obes Metab (2013) 0.97
Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes (2006) 0.96
Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2009) 0.94
Association between C-reactive protein and insulin resistance in a Japanese population: the Minoh Study. Intern Med (2005) 0.93
Association between C-reactive protein and pre-diabetic status in a Chinese Han clinical population. Diabetes Metab Res Rev (2009) 0.89
Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification. J Natl Cancer Inst (2015) 0.88
Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World J Diabetes (2015) 0.87
Hyperinsulinemia, insulin resistance and colorectal adenomas: A meta-analysis. Metabolism (2015) 0.86
Insulin resistance and endometrial cancer risk: A systematic review and meta-analysis. Eur J Cancer (2015) 0.86
Inverse probability weighting in nested case-control studies with additional matching--a simulation study. Stat Med (2013) 0.84
Associations of Coffee Drinking with Systemic Immune and Inflammatory Markers. Cancer Epidemiol Biomarkers Prev (2015) 0.81
GIP contributes to islet trihormonal abnormalities in type 2 diabetes. J Clin Endocrinol Metab (2014) 0.81
Association of inflammatory and other immune markers with gallbladder cancer: Results from two independent case-control studies. Cytokine (2016) 0.81
CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis. Curr Drug Saf (2013) 0.80
Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis. Cytokine (2016) 0.79